Dr. Agarwals Health Care

Lot Size
1 Lot = 35 Qty
Min Investment
₹13370
Subscription
Oversubscribed
Listing Gain
0(Points)

IPO Details

Open Date
Jan 29, 2025
Close Date
Jan 31, 2025
Allotment Date
Feb 03, 2025
Allotment Date
Feb 03, 2025
Refund Initiation
Feb 04, 2025
Demat Transfer
Feb 04, 2025
Listing Date
Feb 05, 2025
Fresh Issue
300
Offer For Sale
2727.26
Issue Price
₹382 to ₹402
Face Value
₹1
Issue Type
Fresh Issue
Total Issue Size
3027.26 CR
QIB + NII Quota
50 + 15%
Retail Quota
35%
Listing On
NSE & BSE
Registrar
KFin Technologies Private Ltd
Check Allotment Status

Company Financial Rusult In Crore

PERIOD ASSET REVENUE PROFIT
30-Sep-2024 3393.41 837.94 39.56
31-Mar-2024 2752.82 1376.45 95.05
31-Mar-2023 1825.17 1031.39 103.23
31-Mar-2022 1026.13 713.78 43.16
DRHP DRAFT

About Dr. Agarwal Health Care
A wide range of eye care services, such as cataract and refractive procedures, consultations, and pharmaceutical goods, are provided by Dr. Agarwals Health Care Limited. The business uses a hub-and-spoke strategy, which allows for effective resource use and geographic expansion. Primary and secondary facilities are referred to as spokes, while the tertiary institution is the hub. The 1994-founded Dr. Agarwals Eye Hospital, a subsidiary listed on the BSE, is owned by Dr. Agarwals Health Care.

As of September 30, 2024, the corporation had 193 facilities across 14 states and 4 union territories in India, comprising 28 hubs and 165 spokes. Its 16 facilities are spread across nine African nations. The companys market share in Indias organised eye care service chain was 25% in FY24.

737 doctors are employed by the company across all of its locations. The company performed 220,523 procedures and treated 21 lakh patients in FY24. In FY24, the hospitals procedures accounted for 64.20% of its entire revenue, followed by the sale of optical products, contact lenses, and accessories (12.83%), and pharmaceuticals related to eye care.

Since FY20, the corporation has purchased more than 60 facilities, including additions in Punjab, Tamil Nadu, and Mumbai. It runs three Centres of Excellence (COEs) with cutting-edge surgical skills and educational initiatives.

 

Strengths and Opportunities

  1. With a 25% market share in FY2024 and revenue that is 1.7 times more than that of the second-largest competitor, Dr. Agarwal Health Care Limited is an eye care chain. To ensure a broad patient base, it has 193 locations throughout India and 16 institutions in nine African nations.
  2. Dr. Agarwals Health Care is the parent company of Dr. Agarwals Eye Hospital, a listed company that was founded in 1994. It owns 71.9% of the company and manages its operations.
  3. complete end-to-end eye care services, including diagnostics, consultations, non-surgical treatments, surgeries, and optical and pharmaceutical goods all under one roof.
  4. Advanced surgical capabilities, integrated pharmacies, and optical counters offer uniform, high-quality patient experiences thanks to standardised operating procedures across locations.

 

Risks and Threats

  1. In the event of terminations or retention issues, reliance on retainership agreements with physicians may have an impact on service quality, patient numbers, and profitability.
  2. The business works in a regulated sector, and noncompliance with environmental, health, safety, or other standards may lead to fines, disruptions, and adverse effects.
  3. The business contributes 42.19% of H1FY25 revenue from its 120 out of 193 sites in Tamil Nadu, Maharashtra, and Karnataka. Unfavourable changes in these states may have an adverse effect on financial and company success.
  4. The business has been the target of complaints, arbitration, and disagreements with physicians on non-compete clauses, which may result in penalties, increased expenses for compliance, and interruptions to business operations.